The XVIII International AIDS Conference presented strong scientific findings on HIV research and program scale-up, emphasizing the need for increased funding and human rights protection. Delegates renewed their commitment to securing universal access to prevention, care, treatment, and support.
The lack of access to scientifically proven interventions for key populations at risk and the lagging scale-up of treatment regimens threaten future progress on AIDS. Organizers call for an end to passive neglect and active denial of life-saving health services, information, and tools.
The International AIDS Society launches a new report recommending a science-based approach to scaling up treatment and prevention of HIV amongst Injecting Drug Users (IDUs). The 'Seek, test, treat and retain' model advocates for expanding outreach, testing, treatment, and retention services within the criminal justice system.
Georgian leaders sign Vienna Declaration to strengthen call for science-based drug policy, emphasizing harm reduction and evidence-based treatment. The declaration aims to improve community health and safety by incorporating scientific evidence into illicit drug policies.
A study of over 1,000 gay and bisexual men found that childhood sexual abuse and social shaming were associated with later psychosocial health problems, including increased risk-taking behavior. The authors suggest that addressing early social issues could help prevent these syndemic conditions.
The International AIDS Conference promotes novel treatment methods, antiretroviral-based prevention options and the development of a cure. Key findings include the potential use of antiretroviral drugs to prevent infections and the need for universal access to lifesaving treatment.
The Case Western Reserve University/University Hospitals Center for AIDS Research has received a five-year, $9 million NIH grant renewal to continue HIV-related research. The funding will support new initiatives on HIV and cancer links, faculty development, and international collaborations.
A global survey of people living with HIV/AIDS found a significant gap in patient-physician dialogue, with discussions often lacking on chronic illnesses, treatment side effects, and co-morbid conditions. Co-morbidities like cardiovascular disease, high cholesterol, and hepatitis C are prevalent among PLWHA.
The CAPRISA 004 trial results demonstrate the effectiveness of a 1% tenofovir gel in reducing a woman's risk of HIV transmission. This breakthrough provides a tool for women to take control of their health and protect themselves from HIV infection.
A UBC-BC CfE study found that increased HAART coverage significantly prevents HIV transmission and reduces new diagnoses in British Columbia. The expansion of HAART treatment plays a crucial role in maximizing public health resources.
The NIH proposes a three-part plan to combat the HIV/AIDS pandemic by significantly expanding antiretroviral therapy access, curing a substantial proportion of infected individuals, and increasing HIV prevention measures. This comprehensive approach aims to control the spread of the disease and ultimately achieve its eradication.
The new guidelines recommend initiating antiretroviral treatment (ART) as soon as possible for asymptomatic individuals with low CD4+ cell counts, and treating symptomatic patients regardless of their CD4+ count. The treatment should be individualized based on concurrent conditions and previous drug exposure.
The International AIDS Society (IAS) has announced the winners of four prestigious scientific awards, recognizing innovative HIV and AIDS research. The Women, Girls and HIV Investigator Prize was awarded to Naina Rani for her work on mainstreaming the Prevention of Parent to Child Transmission program in India.
The International AIDS Society has awarded $3.4 million in grants to 10 early-stage researchers from diverse scientific disciplines, aiming to advance HIV understanding and prevention approaches. The grantees will collaborate with CFAR institutions to explore pressing scientific questions on long-term survival and HIV transmission.
The International AIDS Society and National Institute on Drug Abuse have awarded fellowships to seven young researchers from around the world to study the intersection of drug use and HIV. The recipients will receive US$75,000 each to pursue groundbreaking research in biology, epidemiology, public health, behavioral sciences, and more.
The Fogarty International Center of the NIH has awarded a five-year, $3.6 million grant to an international AIDS training and research program to continue training foreign researchers in developing countries. The program supports established research training programs in India, Cambodia, the Philippines, and Kenya, and will also focus ...
Experts warn that failure to meet universal access pledge and budget cuts to prevention and treatment programs will deliver a major setback. Many African countries face depleting stocks of antiretroviral medications and reduced treatment coverage goals, increasing the risk of HIV drug resistance.
Increasing HAART treatment for people with HIV/AIDS lowers viral load, stops HIV progression, and prevents transmission. A comprehensive economic analysis shows expanding HAART coverage in British Columbia can deliver a net benefit of $900 million over 30 years.
The Vienna Declaration urges governments and international organizations to adopt evidence-based approaches to illicit drug policy, recognizing addiction as a medical condition. This declaration aims to reduce harms deriving from current policies and redirect resources towards prevention, treatment, and harm reduction interventions.
The International AIDS Society calls on donors to uphold their commitment to universal access to HIV prevention, treatment, and care by 2015. Failure to do so would lead to a surge in infections, illness, and death, undermining the credibility of the G8.
The study found that 40-60% of Americans living with HIV/AIDS are smokers, twice the rate in the general population. Researchers emphasize the need for effective interventions to help these individuals quit smoking.
Researchers at Scripps Research Institute have determined the structure of an immune system antibody molecule that effectively acts against most strains of human immunodeficiency virus (HIV). The study advances the effort to develop an AIDS vaccine by providing insights into how broadly neutralizing antibodies work.
Pioneering AIDS researchers Dr. Mark Wainberg and Dr. Norbert Gilmore argue that the current ban on gay men donating blood is no longer justified. They suggest allowing only those in stable, long-term monogamous relationships to donate, while maintaining the ban on those with multiple partners.
New scientific advances offer significant promise for reducing the spread of HIV/AIDS and tuberculosis, including novel TB drugs, rapid diagnostic tests and bold prevention approaches like PrEP. Experts call for policymakers to capitalize on these advances to save millions of lives from these deadly epidemics.
Almost 50% of AIDS patients died from AIDS, but non-AIDS related deaths increased after four years of treatment with ART. Lifestyle-related causes like suicide and liver disease were common non-AIDS deaths.
The International Treatment Preparedness Group's new report documents early warning signs of devastating impact from global pullback on AIDS commitment and funding. People living with HIV often struggle to afford medicines for opportunistic infections, transport costs, food, and second-line medications.
Researchers tracked monocytes in primates infected with simian immunodeficiency virus to find that increased turnover predicts rapid AIDS development and brain disease severity. The study identifies a marker, soluble CD163, exclusive to monocytes, which correlates with disease progression.
In Ghana, large-scale intervention programs have convinced people to trust medical explanations for diseases like HIV/AIDS, overcoming traditional beliefs in witchcraft. The success of long-term health initiatives in Northern regions has shown that education and community engagement can lead to better health outcomes.
The Positive Prevention Toolkit aims to enable HIV/AIDS caregivers to provide prevention messages when interacting with HIV-positive patients. The toolkit consists of seven sections, including training skills, curricula, and practical resources.
The American Association for Dental Research (AADR) awarded John Greenspan the 2010 Distinguished Scientist Award for his groundbreaking research on HIV and its impact on oral health. Greenspan is a renowned expert in the field of oral pathology, having made significant contributions to the development of AIDS research.
Bone-anchored hearing aids significantly improved scores on both hearing tests and questionnaires for children with single-sided deafness. The complication rate was 17%, but the treatment has been shown to be beneficial in counseling children and their families regarding treatment options.
A Cochrane Systematic Review found that home-based nursing in HIV/AIDS patients significantly improves self-reported knowledge of HIV, awareness of medications, and self-reported adherence to medication programmes. Home-based care also had a positive impact on HIV stigma, worry, and physical functioning.
AIDS denialists' refusal to acknowledge HIV treatment benefits led to 330,000 premature deaths in South Africa. The study highlights the need for public health reform and accountability.
Researchers found that higher antiretroviral therapy adherence was associated with lower direct health care costs for HIV-infected adults in South Africa. This decrease in costs is largely attributed to reduced hospital use, saving a median monthly health care cost of $85 per patient.
Scientists at Thomas Jefferson University developed a promising AIDS vaccine using a rabies virus-based strategy, inducing neutralizing antibodies and CD8+ T cell responses in monkeys. The study showed that the vaccine protected against disease and elicited significant antibody activity against SIV.
A new study released on World AIDS Day found that viral failure was twice as likely among patients given Epzicom when compared to those treated with Truvada, especially in those starting therapy with high viral loads. The study also showed a shorter time to virologic failure and adverse events for patients taking Truvada.
Researchers found that unacculturated Hispanics had fewer HIV tests and were more likely to test positive. Interventions must address cultural differences to reduce the growing rate of HIV/AIDS among Hispanics.
A recent study published in BMC Public Health suggests that immediate and aggressive spending of $60 billion on HIV/AIDS treatment could end the epidemic globally. The research, which analyzed a leading-edge mathematical model, predicts that an accelerated approach over five years is necessary to control the spread of the disease.
Researchers at German Cancer Research Center find that HIV virus rarely integrates into genes with high transcription activity. This discovery could lead to the development of specific AIDS drugs targeting these 'cold spots', potentially offering a new approach to combat the virus.
Experts are conducting a large-scale study to measure the hearing of people with HIV/AIDS and compare it to those without, aiming to uncover the relationship between the disease and hearing loss. The research, supported by a $1.9 million grant, will also explore potential factors contributing to age-related hearing loss in these patients.
The article highlights the looming financial pressures in the world's response to HIV/AIDS and neglected tropical diseases. Experts propose various strategies to combat these challenges, including investing in high-impact prevention and efficient treatment efforts, and shifting from emergency responses to evidence-based initiatives. By...
A study published in PLoS Medicine suggests that reducing dropout rates from HIV treatment programs can lead to improved patient survival and cost-effectiveness. The researchers propose strategies such as eliminating co-payments for treatment and increasing services available to patients, which could form part of the commitment to star...
A team of researchers found that interleukin-2 has no effect on the development of AIDS or patient survival. The study, involving over 5000 patients in 25 countries, suggests that IL-2 treatment provides no benefit and does not prevent AIDS-related infectious diseases.
A study published in The Lancet Oncology found that immunodeficiency increases the risk of multiple cancers in HIV patients. Lower CD4 counts were linked to higher risks of certain cancers, while antiretroviral therapy reduced this risk. Effective cancer screening programs are recommended for HIV-positive individuals.
A new study by Dr. Nitika Pant Pai found that only 15% of HIV-positive repeat offenders in San Francisco County jail continued their antiretroviral treatment between incarcerations or after release, increasing the risk of disease progression and public health transmission.
HIV-infected patients are at higher risk for certain non-AIDS-defining malignancies such as anal, lung, Hodgkin's, melanoma and liver cancer. Researchers found a 60% increase in the incidence of these cancers among HIV-positive patients compared to those without HIV.
The HIV Nef protein inhibits cell mobility in immune cells, disrupting their ability to establish contact and combat the virus. This mechanism may lead to the malfunction of B-lymphocytes in AIDS patients.
The Medical College of Wisconsin's Center for AIDS Intervention Research received a five-year, $11.16 million grant from the National Institutes of Health to continue its HIV prevention research. The center will focus on high-risk population segments in the US and expand international HIV prevention programs.
A new once-daily medication has shown to be as effective as multiple dosings for treating the most common mouth infection in HIV/AIDS patients. The treatment, a small tablet applied daily, provides relief from oral candidiasis (OC) with few or no side effects.
Researchers at UC Santa Cruz are working on a new approach to AIDS vaccine development using novel HIV protein structures and broadly neutralizing antibodies to combat the virus' high variability. The $3.5 million NIH grant will support studies exploring these promising findings and potentially lead to more effective vaccines.
A five-year grant will create a comprehensive research infrastructure in the Midwest, focusing on HIV prevention, detection, and treatment. The center will concentrate its investigations around three themes: HIV and women, HIV and aging, and HIV and drug abuse.
Two new broadly neutralizing antibodies (bNAbs) have been discovered to target the HIV virus, providing a promising lead for AIDS vaccine development. The newly found antibodies, PG9 and PG16, attach to a novel site on the virus, making them more accessible for vaccine design.
Researchers have identified two powerful new antibodies to HIV that reveal a potential Achilles heel on the virus. The discovery offers new avenues for designing an effective AIDS vaccine and may lead to the identification of additional vulnerabilities in the virus.
The five-year grant aims to improve the quality of care for women of color suffering from HIV/AIDS by enhancing access and retention in quality HIV care. The project will be implemented in urban centers across America, addressing the technical requirements of HIV clinics serving the medically and economically disadvantaged.
Researchers at the University of Illinois Chicago are developing an educational comic book to teach AIDS patients about food safety, highlighting risks such as listeria and toxoplasmosis. The study aims to improve awareness and reduce life-threatening infections among AIDS patients.
Researchers at the University of Utah created a vaginal gel that turns semisolid in response to semen, trapping AIDS virus particles. The gel, designed to protect women from HIV infection, works by forming a microscopic mesh that blocks the virus from infecting vaginal cells.
Researchers at Yerkes National Primate Research Center propose alternative approaches to developing an effective AIDS vaccine, including making infected individuals resistant to disease progression or reducing the number of cells the virus can infect. They draw inspiration from African nonhuman primates that adapt to HIV-like viruses i...
People living with AIDS are at a higher risk of developing HPV-associated cancers, particularly those with lower CD4 T-cell counts. The study estimates that incidence rates increased across three periods, with the greatest risk observed in invasive anal cancer among men after the introduction of highly active antiretroviral therapy.
A new study reveals that chimpanzees infected with SIV, the precursor to HIV-1, contract and die from AIDS. Infected females were less likely to give birth, and infants born to infected mothers were unlikely to survive. The virus was transmitted sexually and through mother's milk.
Researchers found SIV-infected African wild chimpanzees died prematurely and developed hallmarks of HIV-1 infection, contradicting previous assumption that infected primates wouldn't develop AIDS. Yerkes contributed key comparative data on SIV-infected and uninfected sooty mangabeys, shedding light on mechanisms behind natural immunity.